A200

A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 2975.21m in AUM and 200 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.

Fortescue Metals Group Ltd

FMG

Fortescue Metals Group Ltd. engages in the development of iron ore deposits. The company is headquartered in Perth, Western Australia and currently employs 11,693 full-time employees. The firm is transitioning into a global green energy, metals and products company. Its segments include Metals and Fortescue Future Industries (FFI). The Metals segment is engaged in exploration, development, production, processing, sale and transportation of iron ore, and the exploration for other minerals. Fortescue Future Industries segment is involved in undertaking activities in the global development of green electricity, green hydrogen and green ammonia projects. Through its growth project Iron Bridge and its interest in the Belinga Iron Ore Project in Gabon, it is investing in the growth of its iron ore business. Its operations include three mining hubs in the Pilbara, Western Australia, which are connected to its five berth Herb Elliott Port and the Judith Street Harbour towage infrastructure in Port Hedland by approximately 760 kilometers of the heavy haul railway in the world.

VDHG

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

Vanguard MSCI Index International Shares Etf

VGS

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

Prescient Therapeutics Limited

PTX

Prescient Therapeutics Ltd. is a biopharmaceutical company. The company is headquartered in South Melbourne, Victoria. The firm is engaged in the development of personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 is a compound with the ability to block a cancer growth enzyme, geranylgeranyl transferase-1 (GGT-1). PTX-100 is in Phase Ib expansion cohort study in T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. PTX-200 is in Phase Ib/II trial in relapsed and refractory AML. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M is a platform for enhancing cell therapies by producing cells with superior phenotypes. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy.